BIOPHARMA
By
Will Sanofi’s AI Ethics Revolution Trigger a $100 Billion Shift in Biopharma and Medtech? How the Company’s Transparency Drive is Reshaping Global Healthcare
Key Highlights: AI Ethics at Scale: Sanofi Sets Global Leadership StandardSanofi’s establishment of a dedicated AI Ethical Review…
Can IGC Pharma’s New AI Models Change Alzheimer’s Diagnosis and Drug Discovery for Millions?
New tools unveiled at AAIC 2025 aim to detect Alzheimer’s earlier and faster, even in low-resource settings Key…
Can Absci’s AI-Powered Drug Platform Disrupt $600M+ Biopharma Pipelines by 2026?
Absci blends AI and biology—end-to-endUnlike other AI drug startups that rely on outsourcing, Absci integrates generative AI with…
Can Chugai (Roche subsidiary) and Gero’s $250M AI-Driven Alliance Unlock a New Era in Anti-Aging Therapies?
Key Takeaways: AI-Powered Target Discovery Meets World-Class Antibody EngineeringThe joint research and license agreement between Tokyo-based Chugai Pharmaceutical…
How Is GSK’s Robust Q2 2025 Growth Powering Next-Gen Specialty Medicines and Vaccine Innovation?
Key Highlights Specialty Medicines Fuel Strong Market MomentumGSK’s specialty portfolio, notably in Respiratory, Immunology & Inflammation (+10%) and…
Pfizer Secures Exclusive Global Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
Key Highlights A Bold Bet on BispecificsIn a significant expansion of its oncology pipeline, Pfizer has obtained exclusive…
